Drug compound for resisting against anxiety and improving sleep and application thereof

A composition and drug technology, applied in the field of medicine, can solve problems such as poor drug efficacy and easy drug resistance in patients, and achieve the effects of overcoming poor curative effect, synergistically enhancing anti-anxiety, and reducing toxicity in clinical dosage

Inactive Publication Date: 2018-01-19
GUILIN HAOXIN TECH SERVICE
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Modern medicine has no ideal treatment for insomnia caused by anxiety. For a long time, a single sedative and hypnotic drug has been used. Although it can improve the symptoms to a cert...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] The preparation of embodiment 1 pharmaceutical composition capsule of the present invention

[0017] Prescription: 10 parts by weight of tandospirone citrate, 9 parts by weight of fluoxetine, 15 parts by weight of sertraline hydrochloride, 80 parts by weight of lactose, and 1 part by weight of magnesium stearate;

[0018] Preparation method: Mix and sieve the prescribed amount of tandospirone citrate, fluoxetine, sertraline hydrochloride, lactose and magnesium stearate, and fill them into empty capsules.

Embodiment 2

[0019] The preparation of embodiment 2 pharmaceutical composition granules of the present invention

[0020] Prescription: 10 parts by weight of tandospirone citrate, 9 parts by weight of fluoxetine, 15 parts by weight of sertraline hydrochloride, 80 parts by weight of lactose, 20 parts by weight of microcrystalline cellulose, 4 parts by weight of sodium carboxymethyl starch, Ethanol 20mL;

[0021] Preparation method: mix the prescribed amount of tandospirone citrate, fluoxetine, sertraline hydrochloride, lactose, microcrystalline cellulose, and sodium carboxymethyl starch in a granulator, then add ethanol to make soft Material, vacuum dried, sieved and granulated, and bagged.

Embodiment 3

[0022] The preparation of embodiment 3 pharmaceutical composition tablet of the present invention

[0023] Prescription: 10 parts by weight of tandospirone citrate, 9 parts by weight of fluoxetine, 15 parts by weight of sertraline hydrochloride, 80 parts by weight of lactose, 20 parts by weight of microcrystalline cellulose, 4 parts by weight of sodium carboxymethyl starch, 20 mL of ethanol, 1 part by weight of magnesium stearate;

[0024] Preparation method: mix the prescribed amount of tandospirone citrate, fluoxetine, sertraline hydrochloride, lactose, microcrystalline cellulose, and sodium carboxymethyl starch in a granulator, and then add ethanol to make a soft material , after drying in vacuum, sieve and granulate, then add magnesium stearate, mix evenly, and then compress into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a drug compound for resisting against anxiety and improving sleep and an application thereof. The drug compound comprises the following active ingredients: tandospirone citrate, fluoxetine and sertraline hydrochloride. According to the invention, the tandospirone citrate, fluoxetine and sertraline hydrochloride are jointly used for treating anxiety disorder and insomnia, the defects of poor drug effect and easiness in generating drug dependence of the patient of single drug usage are overcome, the joint use of three drugs has the synergic effects of resisting against anxiety and improving sleep and the function of reducing toxicity can be achieved in the manner of reducing the clinical dosage of one or two drugs.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for anti-anxiety and improving sleep and its application. Background technique [0002] Insomnia is the inability to fall asleep or stay asleep, resulting in a lack of sleep. Also known as sleep and sleep maintenance disorders, it is a common disease caused by various reasons such as difficulty in falling asleep, too short sleep depth or frequency, early awakening and insufficient sleep time or poor quality. Although insomnia is not a critical disease, it often affects the quality of life and hinders people's work, study and health. Long-term insomnia has brought great suffering to people and has become a public health problem more and more. [0003] Many insomnia patients are caused by anxiety. Anxiety is an emotional disorder characterized by persistent tension, worry, fear, or episodic panic, accompanied by autonomic nervous system sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/506A61K31/137A61P25/22A61P25/20
Inventor 钟传新王君
Owner GUILIN HAOXIN TECH SERVICE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap